Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsAgonistic antibodies provide a substantial promise in targeting co-stimulatory receptors and gradually become a powerful tool in the immunotherapy field. There is a growing number of these agents making their way through every stage of antibody research and development. As a prestigious expert in the biomedical market, Creative Biolabs focuses on the key considerations of immune agonist antibody design and devotes to addressing underlying pitfalls during product manufacture, which is a basis of potent combined treatments. More importantly, we offer rational combination therapy services between agonistic antibodies and other candidate therapies, in order to reduce the possible toxicity of combinations and enhance therapeutic efficacy for defined diseases even cancers.
The numerous clinical trials present the overwhelming complexity of the use of agonistic antibodies in combinations for cancer treatments. The antibodies interfere with ligand-receptor interaction, blocking a signaling pathway associated with tumor growth, or identify tumor-associated antigens (TAA), where they induce the death of tumor cells by ADCC, CDC, and ADCP or directly causing apoptosis. When agonistic antibodies can’t kill the tumor cells by themselves, they could be conjugated to cytotoxic drugs to exert this function, or straightly coupled to radio-labeled agents to trigger radiolysis. Furthermore, agonistic antibodies can also be combined with other immune checkpoint antibodies that rather than directed against tumor cells, identify targets on the tumor environment. These comprise antibodies that inhibit tumor-induced vascularization, or against molecules or cells involved in the immune responses.
It is quite obvious that there are several challenges to be settled regarding agonistic antibodies in combinations as antitumor therapeutic agents. One of the most relevant problems is the potential increase of toxicity of combination, concomitant with the rising complexity of the clinical trials. At Creative Biolabs, we have enough capacity to propose varied combinations and carefully evaluate each combined group to decide the conditions giving the highest ratio of efficacy/toxicity. It is of particular interest when the purpose is to destroy the antitumor host immune response, where a small response could not kill the tumor, but an over-response may result in unwanted inflammatory or autoimmune processes. Another relevant challenge is the recognization of new biomarkers, allowing a personalized follow-up of the patient’s status, which would be necessary due to the tumors and the patient’s genotypic and phenotypic differences.
Tab.1 Summary of co‑stimulatory agonist antibodies in clinical development. (Mayes, 2018)
Rational combinations may bring about the simultaneous attack of tumor cells by utilizing the help of own immune cells and exerting broader therapeutic effects, based on a more fast, specific, and robust reaction, trying to imitate the action of the immune system. Creative Biolabs has described how agonistic antibody-based therapies will evolve, involving the usage of antibodies in combinations, their main characteristics and advantages, as well as how they significantly contribute to increasing the chances of success in cancer therapy. Remarkably, we discussed the information on the potential anti-cancer treatments using agonistic antibodies in combinations, either with other antibodies or other biological agents. And our services and research areas include but not limited to the following items.
Antibodies are produced by the immunity’s adaptive arm to protect the organism from pathogens and malignant cells. It should come to no surprise that combination treatments based on agonistic antibodies might be curative and agonistic antibodies’ promote health. As a reliable partner in the antibody development, Creative Biolabs offers one-stop, customized package services to assist clients to accomplish optimal combination therapies of agonistic antibodies and other treatments. For more information, please feel free to contact us.
Reference
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
